The Ratings Game: All eyes will be on Biogen Alzheimer’s results this week — and the stock could swing wildly

When a company releases its financial results, the event is often the defining moment for months. But biopharmaceutical company Biogen Inc.’s Tuesday earnings have been largely overshadowed.

On Wednesday afternoon, the company BIIB, +1.30% plans to present more detailed clinical trial results for one of its drugs at the annual Alzheimer’s Association International Conference in Chicago.

The event is likely to cause “tremendous volatility,” and could either push the stock down $20 or up $40, Leerink analyst Geoffrey Porges said.

Biogen announced earlier this month that the phase 2 trial, testing its BAN2401 therapy in 856 individuals with either early Alzheimer’s disease or mild cognitive impairment due to Alzheimer’s disease, had positive results.

>>> Original Source <<<